| NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis |
|
|
|
Abstract |
2019 |
|
Pankreaskarzinom
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4128 |
|
|
| Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114) |
|
|
|
Abstract |
2019 |
|
Ösophagus-/Magenkarzinome
|
|
|
| doi.org/10.1093/annonc/mdz247.113 |
|
|
| A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) |
|
|
|
Vollpublikation |
2019 |
|
Ösophagus-/Magenkarzinome
|
|
|
| bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5446-2 |
|
|
| Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC) |
|
|
|
Abstract |
2019 |
|
Nierenzellkarzinom
|
|
|
| www.annalsofoncology.org/article/S0923-7534(19)60411-4/pdf |
|
|
| A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) |
|
|
|
Abstract |
2019 |
|
Nierenzellkarzinom
|
|
|
| academic.oup.com/annonc/article/30/Supplement_5/mdz249.055/5576794 |
|
|
| OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) AIO-KHT-0117. |
|
|
|
Abstract |
2019 |
|
Kopf-Hals-Tumoren
|
|
|
| www.annalsofoncology.org/article/S0923-7534(19)59385-1/fulltext |
|
|
| A randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117) |
|
|
|
Abstract |
2019 |
|
Kopf-Hals-Tumoren
|
|
|
| doi.org/10.1093/annonc/mdz252.065 |
|
|
| TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) |
|
|
|
Abstract |
2019 |
|
Kopf-Hals-Tumoren
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6002 |
|
|
| Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial |
|
|
|
Abstract |
2018 |
|
Hepatobiliäre Tumoren / Young Medical Oncologist
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS4145 |
|
|
| A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma (0416-ASG; AB 57/17) |
|
|
|
Poster |
2018 |
|
Urothelkarzinom
|
|
|
|
|
|
